Corneal Neovascularization Clinical Trial
Official title:
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
To determine the effect of subconjunctival Bevacizumab in corneal neovascularization
Corneal transplantation is the most commonly performed transplant surgery in the world
today. Immunologic rejection is the leading cause of graft failure, with about 25% of graft
recipients experiencing at least one episode of rejection. Of these episodes, about 20% are
irreversible. The rate of corneal graft rejection in high-risk eyes, such as corneal
neovascularization, has been reported to be 50% to 70%. Vascularized corneas have a much
higher rate of graft rejection than avascular corneas. Whereas the normal cornea is devoid
of blood and lymphatic vessels, both can invade the cornea secondary to a variety of corneal
diseases and after surgery. This not only reduces visual acuity, but also renders such a
cornea high-risk, if subsequent corneal transplantation is performed.Anti-angiogenesis, the
pharmacologic inhibition of new blood vessel growth and formation, is a new treatment
strategy under active and vigorous investigation. Multiple growth factors have been shown to
contribute to the molecular events involved in the regulation of blood vessel growth
Similarly, it is assumed that angiogenic growth factors such as vascular endothelial growth
factor (VEGF), considered a major pro-angiogenic factor, could play a role in the
pathogenesis of neovascularization.
Several approaches can be taken to neutralize VEGF. Bevacizumab (Avastin) is a full-length
humanized murine monoclonal antibody against the VEGF molecule.It binds to and inhibits the
biologic activity of human VEGF preventing the interaction of this molecule to its receptors
on the surface of endothelial cells. The interaction of VEGF with its receptors leads to
endothelial cell proliferation and new vessel formation.
There is evidence that triamcinolone acetonide (TA) inhibits vasogenic edema and
inflammation, decreases vascular leakage, reduces the secretion of VEGF by pigment
epithelial cells during oxidative stress and, down-regulates the expression of the VEGF gene
in vascular smooth muscle cells Furthermore, TA decreases the paracellular permeability of
cultured epithelial cells and down-regulates the inflammatory expression of endothelial
adhesion molecules.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00004430 -
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
|
N/A | |
Completed |
NCT00769145 -
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
|
Phase 1 | |
Completed |
NCT01257750 -
Treatment of Corneal Neovascularization With Topical Pazopanib
|
Phase 1/Phase 2 | |
Recruiting |
NCT04787471 -
Corneal Crosslinking for Treatment of Corneal Neovascularization
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
Active, not recruiting |
NCT00992849 -
Bevacizumab for the Treatment of Corneal Neovascularization
|
Phase 2 | |
Withdrawn |
NCT00515684 -
Corneal Thinning During Topical Bevacizumab Therapy
|
N/A | |
Terminated |
NCT02797704 -
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
Terminated |
NCT01868360 -
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
|
Phase 1 | |
Withdrawn |
NCT02042027 -
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
|
Phase 1 | |
Recruiting |
NCT04215393 -
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
|
Phase 1 | |
Completed |
NCT00797303 -
The Effect of Bevacizumab on Corneal Neovascularization
|
Phase 4 | |
Recruiting |
NCT05659940 -
Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
|
||
Completed |
NCT00559936 -
Topical Avastin for Treatment of Corneal Neovascularization
|
Phase 1 | |
Completed |
NCT01072357 -
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
Recruiting |
NCT04620109 -
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
|
Phase 1 | |
Completed |
NCT00512876 -
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
|
N/A | |
Recruiting |
NCT05011916 -
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
Completed |
NCT01996826 -
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
Terminated |
NCT00915590 -
Topical IL-1-Ra for Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 |